Key Patent Granted for ORAVEXX by United States Patent and Trademark Office
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORAVEXX™ Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Mar 25, 2022
Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™
Mar 17, 2022
Orcosa Announces Results from Leading Phase 1/2 Clinical Trial Utilizing ORAVEXX™ to be Presented at American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Dec 27, 2021
Statement on Final Patient Dosing in NYU Langone Health’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™
Nov 08, 2021
Statement of Congratulations to Dr. Michael J. Alaia of NYU Langone Health Orthopedic Hospital for Best Paper Award at the 2021 Sir Robert Jones Alumni Scientific Program
« Previous 1 2 3 4 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2024 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement